The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses

Journal of Immunology

Volumn 165, Issue 11, 2000, Pages 6487-6495

  Varga, S M ^a   Wissinger, E L ^a   Braciale, T J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; VIRUS GLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION SYSTEM; LUNG INFILTRATE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; T LYMPHOCYTE; VACCINIA VIRUS;

EID: 0034548224     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.11.6487     Document Type: Article

References (70)

1. Cytokines in the generation of immune responses to and resolution of virus infection
2. + T-cell mechanisms in the control of respiratory virus infections
3. Immunology taught by viruses
4. Risk of primary infection and reinfection with respiratory syncytial virus
5. Respiratory syncytial and parainfluenza viruses
6. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults
7. Viral respiratory infections in the institutionalized elderly: Clinical and epidemiologic findings
8. Respiratory syncytial virus and influenza A infections in the hospitalized elderly
9. An outbreak of respiratory syncytial virus in a bone marrow transplant center
10. Respiratory syncytial virus infection in the elderly
11. Parenteral administration of live respiratory syncytial virus vaccine: Results of a field trial
12. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population
13. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
14. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
15. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
16. + T cells
17. Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus
18. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern
19. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G
20. Distinct types of lung disease caused by functional subsets of antiviral T cells
21. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection
22. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia
23. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus
24. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent
25. Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors
26. Immunological focusing by the mouse major histocompatibility complex: Mouse strains confronted with distantly related lysozymes confine their attention to very few epitopes
27. + T cell epitope on nucleocapsid protein which induces different T-helper cell subsets
28. MHC ligands and peptide motifs: First listing
29. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage
30. Modulation of the immunogenicity of antigenic determinants by their flanking residues
31. Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor
32. + T cells
33. Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins
34. Phenotypic analysis of antigen-specific T lymphocytes
35. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
36. Accessing complexity: The dynamics of virus-specific T cell responses
37. + T cells in the liver during the control and resolution phases of influenza pneumonia
38. + T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy
39. + T cells during the primary immune response to Epstein-Burr virus in vivo
40. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
41. + T cells in primary and secondary influenza pneumonia
42. + T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients
43. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex
44. + T cells in vivo during infection and tumor rejection
45. + T lymphocyte differentiation as a mechanism for subdominant cytotoxic T lymphocyte responses to a viral antigen
46. + T cells during an acute virus infection
47. + T cells during acute infection with lymphocytic choriomeningitis virus
48. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial viral (RSV) infection or immunization with a formalin-inactivated RSV vaccine
49. Quantification of epitope-specific MHC class-II-restricted T cells following lymphocytic choriomeningitis virus infection
50. + T cell interactions in IFN-γ and IL-4 responses to viral infections: Requirements for IL-2
51. + T cells and Th1 dominance during lymphocytic choriomeningitis virus infection
52. Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection
53. Helper T cell differentiation is controlled by the cell cycle
54. Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression
55. Structures of an MHC class II molecule with covalently bound single peptides
56. Crystal structure of I-A(k) in complex with a dominant epitope of lysozyme
57. Molecular components of T-cell recognition
58. Use of global amino acid replacements to define the requirements for MHC binding and T cell recognition of moth cytochrome c (93-103)
59. Crystal structures of two I-A(d)-peptide complexes reveal that high affinity can be achieved without large anchor residues
60. Crystal structure of the human class II MHC protein HLA-DRI complexed with an influenza virus peptide
61. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection
62. + T cells in cell-mediated immunity to LCMV studies in MHC class I and class II deficient mice
63. Tuning into immunological dissonance: An experimental model for infectious mononucleosis
64. Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse models
65. Escape of human immunodeficieney virus from immune control
66. Virologic and immunologic events in primary HIV infection
67. + lymphocytes in vivo
68. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes
69. Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus
70. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice